Have You Been HIT?

Area of Science:

• Vascular Surgery
• Hematology
• Pharmacology

Background:

• Heparin-induced thrombocytopenia (HIT) is a rare immune-mediated complication of heparin therapy.
• HIT poses significant risks of morbidity and mortality, primarily due to thrombosis.
• Clinical suspicion should arise with a platelet count drop of ≥50% within 5-10 days of heparin administration.

Purpose of the Study:

• To provide vascular surgeons with a management guide for heparin-induced thrombocytopenia (HIT).
• To outline diagnostic criteria and treatment strategies for HIT.
• To emphasize the prevention of thrombotic complications associated with HIT.

Main Methods:

• Review of literature on heparin-induced thrombocytopenia (HIT) diagnosis and management.
• Discussion of diagnostic assays, including ELISA and functional platelet activation assays.
• Guidance on immediate cessation of heparin and initiation of alternative anticoagulation.

Main Results:

• The primary complication of HIT is thrombosis; bleeding is surprisingly rare.
• Confirmation of HIT relies on detecting HIT antibodies via ELISA or functional assays.
• Delayed initiation of warfarin until platelet recovery and a 5-day overlap with alternative anticoagulants are recommended.

Conclusions:

• Immediate cessation of heparin is paramount upon clinical suspicion of HIT.
• Alternative anticoagulation is necessary for 2-3 months to prevent recurrent thrombosis.
• Careful management of anticoagulation, including warfarin initiation, is essential for optimal patient outcomes.